Abstract
As Alzheimer's disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans ε-viniferin induced the disaggregation of Aβ42 peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans ε-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / pathology
-
Animals
-
Astrocytes / drug effects
-
Astrocytes / pathology
-
Benzofurans / pharmacokinetics
-
Benzofurans / therapeutic use*
-
Disease Models, Animal
-
Female
-
Inflammation / drug therapy*
-
Inflammation / pathology
-
Male
-
Mice
-
Mice, Transgenic
-
Microglia / drug effects
-
Microglia / pathology
-
Plaque, Amyloid / drug therapy*
-
Plaque, Amyloid / pathology
-
Stilbenes / pharmacokinetics
-
Stilbenes / therapeutic use*
Substances
-
Benzofurans
-
Stilbenes
-
epsilon-viniferin
Grants and funding
This work was not supported by any research grant. Financial support came only from the EA3808 dotation from the French Ministry of Education and Research and Technology.